Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

ImmunityBio announces positive study results for ‘Kick and Kill’ HIV cure strategy to reduce HIV viral load with Anktiva therapy
ImmunityBio announces positive study results for ‘Kick and Kill’ HIV cure strategy to reduce HIV viral load with Anktiva therapy
ImmunityBio, Inc., a clinical-stage immunotherapy company, announced promising study results that demonstrate the activation of CD4+ and CD8+ T cells and natural killer (NK) cells in people living ...
Oxford Biomedica, Homology Medicines to create AAV manufacturing JV in US
Oxford Biomedica, Homology Medicines to create AAV manufacturing JV in US
Oxford Biomedica, a UK-based gene and cell therapy company, has agreed to form a joint venture (JV) to undertake an adeno-associated virus (AAV) manufacturing and innovation business in the US with...
Lilly to build $1bn manufacturing plant in Concord, North Carolina
Lilly to build $1bn manufacturing plant in Concord, North Carolina

Eli Lilly and Company (Lilly) said that it will invest more than $1 billion to build a new manufacturing plant in Concord, North Carolina.

Pfizer and Ionis End Vupanorsen Program for Heart Disease
Pfizer and Ionis End Vupanorsen Program for Heart Disease
After disappointing phase 2 results, Pfizer and Ionis Pharmaceuticals have scrapped their development program for vupanorsen for heart disease and severe hyperglyceridemia indications. ...
China NMPA accepts BeiGene’s sNDA for Brukinsa to treat CLL and grants breakthrough therapy designation
China NMPA accepts BeiGene’s sNDA for Brukinsa to treat CLL and grants breakthrough therapy designation
BeiGene, a global, science-driven biotechnology company, announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental...
EU Approves Pfizer’s Lorviqua for Treating ALK-Positive Advanced Lung Cancer
EU Approves Pfizer’s Lorviqua for Treating ALK-Positive Advanced Lung Cancer
The European Commission has granted Pfizer’s Lorviqua (lorlatinib) — branded in the U.S. as Lorbrena — marketing authorization as a first-line treatment for adults with anaplastic lymphoma ki...
Glenmark Pharma arm gets final USFDA approval for blood pressure drug
Glenmark Pharma arm gets final USFDA approval for blood pressure drug
Glenmark Pharmaceuticals Ltd on Thursday said its US subsidiary has received final approval from the country’s health regulator (FDA) for its generic Bisoprolol Fumarate and Hydrochlorothiazide t...
Senhwa's Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations
Senhwa's Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations
Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that the US Food and...
Samsung shells out $2.3 billion for Biogen stake in biosimilar joint venture
Samsung shells out $2.3 billion for Biogen stake in biosimilar joint venture
Samsung Biologics announced Thursday that it has agreed to buyout Biogen's stake in their nearly decade-long biosimilars joint venture Samsung Bioepis for $2.3 billion.  ...
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antig...
U.S. FDA declines to approve Merck's cough treatment
U.S. FDA declines to approve Merck's cough treatment
Merck & Co said the U.S. Food and Drug Administration declined to approve its experimental drug for the treatment of chronic cough and sought additional information on the treatment's effective...
Omicron relief: Pfizer and BioNTech initiate study into targeted vaccine
Omicron relief: Pfizer and BioNTech initiate study into targeted vaccine

COVID-19 vaccine luminaries Pfizer and BioNTech study will examine data from the current booster and consider need for specific Omicron jab.

Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand